Skip to Main Content (Press Enter)

Logo UNIMI
  • ×
  • Home
  • Persone
  • Attività
  • Ambiti
  • Strutture
  • Pubblicazioni
  • Terza Missione

Expertise & Skills
Logo UNIMI

|

Expertise & Skills

unimi.it
  • ×
  • Home
  • Persone
  • Attività
  • Ambiti
  • Strutture
  • Pubblicazioni
  • Terza Missione
  1. Attività

Low density lipoprotein receptor (LDLR)-independent effects of proprotein convertase subtilisin/kexin type 9 (PCSK9): role in modulating insulin-resistance, ectopic fat accumulation and low-grade inflammation

Progetto
The wealth of evidence, from epidemiological studies to randomized clinical trials, consistently shows that low-density lipoprotein cholesterol (LDL-C) is causally associated with cardiovascular disease. These studies also show that lowering LDL-C levels reduces the risk of cardiovascular events proportional to the absolute reduction in LDL-C. Blood LDL-C levels are under the control of several metabolic pathways, including the proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a plasma protein, mainly of hepatic origin, that mediates the degradation of the LDL receptor (LDLR) and affecting the LDL-C uptake. Nevertheless, experimental evidence supports the role of PCSK9 on insulin resistance, visceral adiposity, ectopic fat accumulation, post-prandial hypertriglyceridemia and low-grade inflammation. These effects are mainly independent from LDLR, and are mediated by the very low-density lipoprotein receptor (VLDLR) and the scavenger receptor CD36, additional targets of PCSK9. PCSK9-mediated CD36 degradation was proposed to limit fatty acid uptake and TG accumulation in tissues, such as the liver. In parallel, studies using transgenic animals with the specific inactivation of PCSK9 in the liver further showed that VLDLR expression is regulated by circulating PCSK9. These data suggest the possibility that, by targeting VLDLR and/or CD36, PCSK9 may also modulate the TG uptake by adipose tissue and intestinal absorption. The link between PCSK9 and metabolic dysfunction extends also beyond VLDLR and CD36 modulation, as PCSK9 is expressed also in the pancreas. Cholesterol homeostasis is crucial for pancreatic β-cells function and survival; excessive cholesterol accumulation causes a significant reduction in islets’ ability to secrete insulin in response to glucose, and prolonged exposure to high levels of LDL or VLDL could be lethal for β cells. PCSK9 deficient mice present an altered morphology of pancreatic islets, although it is not clear whether this is associated with impaired insulin secretion. Additional observations have strengthened the link between PCSK9 and glucose: a genetic score consisting of independently inherited polymorphisms in the PCSK9 gene in more than 110,000 subjects, although resulting in reduced LDL-C levels and cardiovascular events, associates with an increased risk of diabetes. Several observations have also pointed the attention on the role of PCSK9 in inflammation. For instance, i) PCSK9 levels correlate with white blood cells count in patients with stable CAD; ii) PCSK9 inhibition with siRNA inhibits the OxLDL-mediated response in cultured macrophages and reduces vascular inflammation in apoE null mice, fed a HFD; iii) in hypercholesterolemic mice, mAb anti PCSK9 reduces inflammatory monocyte recruitment; iv) PCSK9 induces a pro-inflammatory phenotype in cultured macrophages; v) overexpression of PCSK9 in mice increases vascular inflammation. Based on these observations, the main aim of the present study will be to provide new experimental and clinical insights on the pathological significance of PCSK9-mediated CD36 and VLDLR degradation on triglyceride-rich lipoprotein (TGRL) metabolism, ectopic fat accumulation, inflammation and insulin resistance. This action of PCSK9 will be investigated in both clinical and experimental settings. Subjects with genetic variants on CD36 and VLDLR genes will be first identified and then characterized in for visceral and subcutaneous adipose tissue, insulin resistance and inflammatory status. Hyperinsulinemic-euglycemic clamp will be utilized to assess insulin resistance status. These analyses will be then integrated with ex-vivo studies on human atherosclerotic plaque specimens, plasma levels of PCSK9, and proinflammatory mediators. Finally, in vivo (transgenic and knock-out mice) and in vitro (genetically modified cultured cells) experimental approaches will be utilized in order to define th
  • Dati Generali
  • Aree Di Ricerca
  • Pubblicazioni

Dati Generali

Dipartimenti coinvolti

Dipartimento di Scienze Farmacologiche e Biomolecolari Rodolfo Paoletti   Principale  

Tipo

PRIN2017 - PRIN bando 2017

Finanziatore

MINISTERO DELL'ISTRUZIONE E DEL MERITO
Organizzazione Esterna Ente Finanziatore

Capofila

UNIVERSITA' DEGLI STUDI DI MILANO

Periodo di attività

Agosto 29, 2019 - Agosto 28, 2022

Durata progetto

36 mesi

Aree Di Ricerca

Settori


Settore BIO/14 - Farmacologia

Pubblicazioni

Pubblicazioni (7)

Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemia 
EUROPEAN HEART JOURNAL
OXFORD UNIVERSITY PRESS
2025
Articolo
Altmetric disabilitato. Abilitalo su "Utilizzo dei cookie"
High dietary inflammatory index associates with inflammatory proteins in plasma. 
DIABETOLOGY & METABOLIC SYNDROME
BIOMED CENTRAL
2024
Articolo
Open Access
Altmetric disabilitato. Abilitalo su "Utilizzo dei cookie"
Plasma proteins associate with carotid plaques and predict incident atherosclerotic cardiovascular events 
VASCULAR PHARMACOLOGY
ELSEVIER
2024
Articolo
Open Access
Altmetric disabilitato. Abilitalo su "Utilizzo dei cookie"
The 'environmental exposome' as a target to reimagine the cardiovascular prevention 
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
OXFORD ACADEMIC
2024
Articolo
Altmetric disabilitato. Abilitalo su "Utilizzo dei cookie"
Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors 
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
OXFORD ACADEMIC
2022
Articolo
Reserved Access
Altmetric disabilitato. Abilitalo su "Utilizzo dei cookie"
Inclisiran : How widely and when should we use it? 
CURRENT ATHEROSCLEROSIS REPORTS
SPRINGER
2022
Articolo
Open Access
Altmetric disabilitato. Abilitalo su "Utilizzo dei cookie"
Lipid Clinics Network. Rationale and design of the EAS global project 
ATHEROSCLEROSIS SUPPLEMENTS
ELSEVIER
2020
Articolo
Open Access
Altmetric disabilitato. Abilitalo su "Utilizzo dei cookie"
  • Informazioni
  • Assistenza
  • Accessibilità
  • Privacy
  • Utilizzo dei cookie
  • Note legali

Realizzato con VIVO | Progettato da Cineca | 25.11.5.0